(Rev. 03/01) TD. 17	DEPARTMENT OF COMMERCE J.S. Patent and Trademark Office
OMB No. 0651-0027 (exp. 5/31/2002)  Tab settings ⇔ ⇔ ▼ ▼ ▼	A A A A
To the Honorable Commissioner of Patents and Trademarks: F	
1. Name of conveying party(ies):  Forest Pharmaceuticals, Inc.  7-14-32	2. Name and address of receiving party(ies)  Name: Propst Pharmaceuticals, LLC Internal
Individual(s)  General Partnership  Corporation-State Delaware  Other	Address:Street Address:_1236
Additional name(s) of conveying party(ies) attached? 📮 Yes 🛣 No	Association  General Partnership
3. Nature of conveyance:	Limited Partnership
Assignment	Corporation-State
Security Agreement Change of Name  Other Security Interest terminated  Execution Date: July 26, 2002	Other Limited Liability Company - Alabama If assignee is not domiciled in the United States, a domestic representative designation is attached:  (Designations must be a separate document from assignment) Additional name(s) & address(es) attached?  Yes No
A. Trademark Application No.(s)  Additional number(s) att	B. Trademark Registration No.(s) 2509656  tached Yes No
Name and address of party to whom correspondence concerning document should be mailed:  Name: Melissa Cooper	6. Total number of applications and registrations involved:
Name: Melissa Cooper  Dornbush Mensch Mandelstam  Internal Address: & Schaeffer, LLP	7. Total fee (37 CFR 3.41)\$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Street Address: 747 Third Avenue	8. Deposit account number:
City: New York State: NY Zip: 10017	(Attach duplicate copy of this page if paying by deposit account)
9. Statement and signature. To the best of my knowledge and belief, the foregoing information copy of the original document.  Michael Baker	
	gnature Date

40 - Mail documents to be recorded with required cover sheet information to:
Commissioner of Patent & Trademarks, Box Assignments
Washington, D.C. 20231



## FOREST PHARMACEUTICALS, INC.

Subsidiary of Forest Laboratories, Inc.

## INWOOD LABORATORIES, INC.



MICHAEL F. BAKER
Executive Vice President
Trade Sales & Development

July 26, 2002

## **VIA FACIMILE & FIRST CLASS MAIL**

A. Mac Martinson, Esq.Martinson & Beacon, P.C.115 North Side SquareHuntsville, Alabama 35801

Re:

Vintage Pharmaceuticals, Inc. - Forest Pharmaceuticals Inc.

Purchase Agreement dated August 14, 2000 (the "Agreement").

Dear Mr. Martinson:

Reference is made to the Purchase Agreement ("Agreement") dated August 14, 2000 between Forest Pharmaceuticals Inc. ("Forest") and Vintage Pharmaceuticals, Inc. ("Vintage"). By this letter, we confirm that Vintage has satisfied its payment obligations under the above referenced Agreement and accordingly Forest no longer has a security interest in the assets purchased pursuant to the Agreement.

Simultaneously with the mailing of this letter, Forest has filed a UCC-3 Financing Statement Amendment in Alabama which terminates the UCC-1 financing statement filed on September 29, 2000. A copy of the UCC-3 termination statement is enclosed for your records. In addition, Forest has sent a copy of this letter to be recorded with the U.S. Patent and Trademark Office as evidence that the security interest is no longer in effect with respect to the Endal<sup>TM</sup> mark (Registration No. 2509656).

Please do not hesitate to contact me with any questions or comments regarding the enclosed.

Michael J. Buke

Michael F. Baker

Encl.

cc:

Melissa Cooper, Esq. (w/encl.)

RECORDED: 08/14/2002

909 Third Avenue • New York, NY 10022 • (212) 224-6719 • (800) 947-5227 • Fax (212) 224-6740

TRADEMARK

REEL: 2563 FRAME: 0564